Reversal of taxol resistance by cisplatin in nasopharyngeal carcinoma by upregulating thromspondin-1 expression

Anti-Cancer Drugs

Volumn 21, Issue 4, 2010, Pages 381-388

  Peng, Xiaowei ^a   Li, Wei ^a   Tan, Guolin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apoptosis; Cisplatin; Drug resistance; Nasopharyngeal carcinoma; Taxol; Thromspondin 1

Indexed keywords

CISPLATIN; GLYCOPROTEIN P; MESSENGER RNA; PACLITAXEL; TAXOL RESISTANT PROTEIN 1; THROMSPONDIN 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; NASOPHARYNGEAL NEOPLASMS; PACLITAXEL; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; THROMBOSPONDIN 1; UP-REGULATION;

EID: 77949411149     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283363980     Document Type: Article

References (31)

1. Gallimore AP. Nasopharyngeal carcinoma. Clin Oncol 1995; 7:388-393.
2. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365:2041-2054.
3. Wang X, Masters JR,Wong YC, Lo AK, Tsao SW. Mechanism of differential sensitivity to cisplatin in nasopharyngeal carcinoma cells. Anticancer Res 2001; 21:403-408.
4. Cheung HW, Jin DY, Ling MT, Wong YC, Wang Q, Tsao SW, et al. Mitotic arrest deficient 2 expression induces chemosensitization to a DNAdamaging agent, cisplatin, in nasopharyngeal carcinoma cells. Cancer Res 2005; 65:1450-1458.
5. Leong SS, Wee J, Rajan S, Toh CK, Lim WT, Hee SW, et al. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. Cancer 2008; 113:1332-1337.
6. Hussain M, Gadgeel S, Kucuk O, Du W, Salwen W, Ensley J. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck. Cancer 1999; 86:2364-2369.
7. Tan EH, Khoo KS, Wee J, Fong KW, Lee KS, Lee KM, et al. Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma. Ann Oncol 1999; 10:235-237.
8. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993; 15:55-61.
9. Bradley G, Ling V. P-Glycoprotein, multidrug resistance and tumor progression. Cancer Metastasis Rev 1994; 13:223-233.
10. Monzó M, Rosell R, Sánchez JJ, Lee JS, O'Brate A, Gonzá lez-Larriba JL, et al. Paclitaxel resistance in non-small-cell lung cancer associated with tubulin gene mutations. J Clin Oncol 1999; 17:1786-1793.
11. Lih CJ,Wei W, Cohen SN. TXR1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes. Genes Dev 2006; 20:2082-2095.
12. Van Amerongen R, Berns A. TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes Dev 2006; 20:1975-1981.
13. Pires MM, Emmert D, Hrycyna CA, Chmielewski J. Inhibition of P-glycoprotein-mediated paclitaxel resistance by reversibly linked quinine homodimers. Mol Pharmacol 2009; 75:92-100.
14. Quan F, Pan C, Ma Q, Zhang S, Yan L. Reversal effect of resveratrol on multidrug resistance in KBv200 cell line. Biomed Pharmacother 2008; 62:622-629.
15. Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P, et al. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res 2001; 3:253-263.
16. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2003; 2:105-112.
17. Li GY, Liu JZ, Zhang B, Wang LX,Wang CB, Chen SG. Cyclosporine diminishes multidrug resistance in K562/ADM cells and improves complete remission in patients with acute myeloid leukemia. Biomed Pharmacother 2009; 63:592-598.
18. Peng X, He G, Tan G. Tan Expression of ATP-binding cassette transporters in a paclitaxel-resistant nasopharyngeal carcinoma cell line. Chinese J Otorhinolaryngol-Skull Base Surg 2008; 14:15-20.
19. Chu Y, Tan G, Ma Y. Establishment of a paclitaxel-resistant human nasopharyngeal carcinoma cell line and study of its mechanisms. Chinese J Otorhinolarygol-Skull Base Surg 2007; 13:411-414.
20. Chou TC, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983; 4:450-454.
21. Zhao L, Wientjes MG, Au JL. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10:7994-8004.
22. Tan G, Li H, Chen J, Jiang M, Ma Y, Liu X, et al. Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells. Int J Cancer 2002; 97:168-172.
23. Blagosklonny MV. Targeting cancer cells by exploiting their resistance. Trends Mol Med 2003; 9:307-312.
24. Yoshikawa M, Ikegami Y, Hayasaka S, Ishii K, Ito A, Sano K, et al. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells. Int J Cancer 2004; 110:921-927.
25. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7:1429-1437.
26. Minderman H, Brooks T, O'Loughlin KL, Ojima I, Bernacki RJ, Baer MR. Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel and tRA96023. Cancer Chemother Pharmacol 2004; 53:363-369.
27. Ojima I, Chen J, Sun L, Borella CP, Wang T, Miller ML, et al. Design, synthesis, and biological evaluation of new-generation taxoids. J Med Chem 2008; 51:3203-3221.
28. Aoki Y, Kurata H, Watanabe M, Fujita K, Tanaka K. Combination chemotherapy with irinotecan hydrochloride (CPT-11) and mitomycin C in platinum-refractory ovarian cancer . Am J Clin Oncol 2004; 27:461-464.
29. Hogberg T, Glimelius B, Nygren P. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001; 40:340-360.
30. Van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G. Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 1998; 5:249-255.
31. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005; 11:298-305.